Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk (NYSE:NVO) and maintained a $160 price target.
September 20, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk, maintaining a $160 price target, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and maintenance of a $160 price target by a reputable analyst suggests positive sentiment and potential upside for Novo Nordisk's stock. This could lead to increased investor confidence and buying interest in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100